Literature DB >> 28815756

Can ad hoc analyses of clinical trials help personalize treatment decisions?

Eman Biltaji1,2,3, Shaun S Kumar1, Elena Y Enioutina1,4, Catherine M T Sherwin1,2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28815756      PMCID： PMC5651315          DOI： 10.1111/bcp.13377

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.

Authors:  Peter A Calabresi
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

2.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

Review 3.  Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.

Authors:  Martin Frank; Thomas Mittendorf
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

4.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

5.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

6.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

7.  KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

8.  KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

Authors:  William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold E Varmus
Journal:  PLoS Med       Date:  2005-01-25       Impact factor: 11.069
  8 in total
  1 in total

1.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Authors:  Jasmine A Luzum; Jason C Cheung
Journal:  Pharmacogenomics       Date:  2018-09-10       Impact factor: 2.533
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.